Kawada-Watanabe E, et al. - This subanalysis of the HIJ-PROPER study, which included 1,734 study participants, investigated the effects of high-sensitivity C-reactive protein (hsCRP) level and estimated glomerular filtration rate (eGFR) level on the prognosis for patients with acute coronary syndrome undergoing aggressive lipid-lowering therapy in contemporary practice. Participants were categorized into four groups using an hsCRP value of 10 mg/L and an eGFR value of 60 mL/min/1.73 m² as the cut-off points: group A, low hsCRP and normal or mild renal impairment; group B, low hsCRP and renal impairment; group C, high hsCRP and normal or mild renal impairment; and group D, high hsCRP and renal impairment. The median follow-up period was 3.9 years, and the follow-up rate was 99%. Findings showed that, irrespective of renal impairment and aggressive lipid-lowering therapy, patients with elevated levels of hsCRP had worse prognoses.